Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Accumulated Expenses: 2012-2025

Historic Accumulated Expenses for Veracyte (VCYT) over the last 12 years, with Sep 2025 value amounting to $48.4 million.

  • Veracyte's Accumulated Expenses rose 10.26% to $48.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.4 million, marking a year-over-year increase of 10.26%. This contributed to the annual value of $43.8 million for FY2024, which is 14.05% up from last year.
  • Per Veracyte's latest filing, its Accumulated Expenses stood at $48.4 million for Q3 2025, which was up 10.68% from $43.7 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's Accumulated Expenses ranged from a high of $48.4 million in Q3 2025 and a low of $16.3 million during Q1 2021.
  • Over the past 3 years, Veracyte's median Accumulated Expenses value was $38.4 million (recorded in 2023), while the average stood at $38.9 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 237.25% in 2021, then fell by 20.50% in 2023.
  • Veracyte's Accumulated Expenses (Quarterly) stood at $39.5 million in 2021, then decreased by 4.31% to $37.8 million in 2022, then grew by 1.73% to $38.4 million in 2023, then grew by 14.05% to $43.8 million in 2024, then rose by 10.26% to $48.4 million in 2025.
  • Its Accumulated Expenses was $48.4 million in Q3 2025, compared to $43.7 million in Q2 2025 and $35.9 million in Q1 2025.